Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 28;142:111957. doi: 10.1016/j.biopha.2021.111957

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 4 — A strategy for producing personalized viral-specific T cells as a possible therapeutic for preventing and/or treating SARS-CoV-2 infections in susceptible communities, including cancer patients. SARS-CoV-2 peptides are pulsed into an individual's monocytic-DCs and are then used to prime the same individual's T cells, resulting in SARS-CoV-2-specific T cells. These T cells may be cryopreserved or infused into the vulnerable individual as prevention or treatment against COVID-19 [66], [67], [68].